Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

  title={Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention},
  author={Zobair M. Younossi and Quentin Mark Anstee and Milena Marietti and Timothy Hardy and Linda Henry and Mohammed Eslam and Jacob George and Elisabetta Bugianesi},
  journal={Nature Reviews Gastroenterology \& Hepatology},
NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for… 

An Algorithmic Approach to NAFLD Screening: From PCP to Specialist

Emerging evidence shows that early diagnosis and management of NAFLD may mitigate these complications while also reducing health-related and economic burden of disease.

NAFLD as the metabolic hallmark of obesity.

Efforts should be made for a better and more accurate baseline diagnosis, identification of patients at higher risk for progression to NASH as well as adequate treatment, to allow us to offer a personalized approach in NAFLD in the context of precision medicine.

Changing clinical management of NAFLD in Asia

Accumulating evidence indicates that NAFLD is associated with various extrahepatic comorbidities such as cardiovascular disease, chronic kidney disease, malignancy, in addition to liver‐specific complications, and should be managed as a multisystem disease in conjunction with metabolic syndrome.

The global, regional, and national burden and trends of NAFLD in 204 countries and territories: an analysis from Global Burden of Disease 2019

Background Nonalcoholic fatty liver disease (NAFLD) poses a substantial socioeconomic burden and is becoming the fastest-growing driver of chronic liver disease, potentially accompanied by a poor

Genes and NAFLD/NASH Progression

An overview of current knowledge pertaining to the genetic and epigenetic basis of NAFLD, the potential translational implications of this knowledge, current challenges and perspectives on the future of advances in this field for precision medicine are provided.

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease

The characteristics and prevalence of nonalcoholic fatty liver disease are summarized and the status of the understanding of its mechanisms and potential therapeutic targets are summarized.

Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions

Non-alcoholic fatty liver disease (NAFLD) affects over 30% of the United States population and is projected to become a leading cause of chronic liver disease by 2020. As a result, the economic and

Clinical workup of fatty liver for the primary care provider

Treatment of nonalcoholic fatty liver disease is limited mainly to lifestyle modifications to promote weight loss along with consideration for off-label use of certain medications, but recent progression in clinical trials means more effective treatments are on the horizon.



Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

The evidence that suggests NAFLD is a multisystem disease and the factors that might determine interindividual variation in the development and progression of its major hepatic and extrahepatic manifestations are reviewed.

Survey of health status , nutrition and geography of food selection of chronic liver disease patients

An interesting interdisciplinary effort to apply GIS to the study of food habits of CLD patients in a country characterized by high average wealth and many food choices is reported.

The genetics of NAFLD

The current status of the field is described, discussing specific genetic and epigenetic modifiers, including the mechanisms through which genes identified by genome-wide association studies, including PNPLA3, influence disease progression.

Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations

The unprecedented rise in the prevalence of NAFLD globally requires an initiation of population cohort studies with long-term follow-up to determine the incidence and natural history ofNAFLD and its underrepresentation in African-Americans.

Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

NAFLD patients have increased risk of death, with a high risk ofdeath from cardiovascular disease and liver‐related disease, and the NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease‐specific mortality.

Nonalcoholic Fatty Liver Disease in Latinos.